Leukemias and Myelodysplastic Syndromes

Expert faculty review and share their insights on key findings in leukemias and myelodysplastic syndromes presented at the 2023 ASH Annual Meeting. 

Share

Program Content

Activities

  • ASH 2023 Data in Leukemias and MDS
    Conference to Clinic: Leukemias and Myelodysplastic Syndromes
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 10, 2024

  • ASH 2023: Leukemias and MDS
    Key Studies in Leukemias and Myelodysplastic Syndromes: Independent Conference Coverage of ASH 2023
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 06, 2024

    Expires: March 05, 2025

Activities

COMMANDS Full Analysis
COMMANDS: Full Analysis of Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

IMerge Subgroup Analysis
Phase III IMerge Subgroup Analysis: Imetelstat for Achieving Transfusion Independence in ESA R/R or Ineligible Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Retrospective STOP-VEN Study
STOP-VEN: Discontinuation of Venetoclax + Azacitidine for Patients With AML in Remission at Time of Treatment Interruption
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Quizartinib, Ven, Dec in FLT3 ITD Mutated AML
Phase I/II Trial of Quizartinib, Venetoclax, and Decitabine in FLT3-ITD–Mutated AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Oral AAA in ND APL
All-Oral Arsenic Trioxide–Based Induction in Newly Diagnosed Acute Promyelocytic Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

ASCEND-CML
ASCEND-CML: Phase II Trial of Frontline Asciminib in Patients With CP-CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Revumenib for Acute Leukemia
AUGMENT-101: Phase II Study of Revumenib for R/R KMT2Ar Acute Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

QuANTUM-First  MRD Analysis
Phase III QuANTUM-First: Prognostic Value of FLT3-ITD–Specific MRD Clearance at Induction/Consolidation Using Chemotherapy With or Without Quizartinib in Patients With AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2023

STIMULUS-AML2
STIMULUS-AML2: Preliminary Safety of Sabatolimab Monotherapy in Patients With MRD+ AML After AlloSCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.